Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease

(2012) Matthew J Betts et al.   BRITISH JOURNAL OF PHARMACOLOGY

New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

(2012) Fabio Blandini et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic?

(2012) Filippo Caraci et al.   NEUROCHEMISTRY INTERNATIONAL

Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model

(2012) Ming-Hong Hsieh et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys

(2011) G. J. Masilamoni et al.   BRAIN

Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias

(2011) Imtiaz Ahmed et al.   BRAIN

Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions

(2011) Li Chen et al.   BRAIN RESEARCH BULLETIN

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

(2011) Susan Duty et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata

(2011) M Broadstock et al.   BRITISH JOURNAL OF PHARMACOLOGY

Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats

(2011) Kristin B. Dupre et al.   EXPERIMENTAL NEUROLOGY

Discovery, Synthesis, and Structure–Activity Relationship Development of a Series ofN-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4) with Oral Efficacy in an Antiparkinsonian Animal Model

(2011) Carrie K. Jones et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Metabotropic Glutamate Receptor 7 Allosteric Modulator AMN082: A Monoaminergic Agent in Disguise?

(2011) S. J. Sukoff Rizzo et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease

(2011) Andrew Lees et al.   MOVEMENT DISORDERS

Etiology and pathogenesis of Parkinson's disease

(2011) Anthony H. Schapira et al.   MOVEMENT DISORDERS

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias

(2011) Fabrizio Gardoni et al.   NEUROBIOLOGY OF AGING

GluR1 Phosphorylation and Persistent Expression of Levodopa-induced Motor Response Alterations in the Hemi-Parkinsonian Rat

(2011) Maowen Ba et al.   NEUROCHEMICAL RESEARCH

Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia

(2011) Bernardino Ossola et al.   NEUROPHARMACOLOGY

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys

(2011) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia

(2011) M.M. Iravani et al.   PARKINSONISM & RELATED DISORDERS

Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease

(2011) Véronique Sgambato-Faure et al.   PROGRESS IN NEUROBIOLOGY

Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia

(2011) Joanna M. Wierońska et al.   PSYCHOPHARMACOLOGY

Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease

(2010) G. Ambrosi et al.   BRAIN RESEARCH BULLETIN

Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease

(2010) Susan Duty   BRITISH JOURNAL OF PHARMACOLOGY

Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease

(2010) PJ Austin et al.   BRITISH JOURNAL OF PHARMACOLOGY

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease

(2010) Christopher Kobylecki et al.   JOURNAL OF NEUROCHEMISTRY

The clinical spectrum of levodopa-induced motor complications

(2010) E. Hametner et al.   JOURNAL OF NEUROLOGY

Management of punding in Parkinson’s disease: an open-label prospective study

(2010) A. Fasano et al.   JOURNAL OF NEUROLOGY

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap

(2010) Paolo Calabresi et al.   LANCET NEUROLOGY

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

(2010) Murat Emre et al.   LANCET NEUROLOGY

Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies  -Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective

(2010) F. Caraci et al.   MOLECULAR PHARMACOLOGY

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

(2010) Elisabeth Wolf et al.   MOVEMENT DISORDERS

Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study

(2010) Karla Eggert et al.   MOVEMENT DISORDERS

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

(2010) Daniella Rylander et al.   NEUROBIOLOGY OF DISEASE

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

(2010) Nicolas Morin et al.   NEUROPHARMACOLOGY

Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems

(2010) Joanna M. Wierońska et al.   NEUROPHARMACOLOGY

MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism

(2010) Melanie A. Paquette et al.   NEUROPHARMACOLOGY

Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias

(2010) B. Ouattara et al.   NEUROSCIENCE

Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease

(2010) Yolanda D. Black et al.   NEUROSCIENCE LETTERS

Glutamate receptors, neurotoxicity and neurodegeneration

(2010) Anthony Lau et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia

(2010) Emanuela Santini et al.   PLoS One

Characterisation of the Expression of NMDA Receptors in Human Astrocytes

(2010) Ming-Chak Lee et al.   PLoS One

The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2

(2009) Pier L. D’Alessandro et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism

(2009) Corinne Beurrier et al.   FASEB JOURNAL

Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

(2009) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson’s disease treatment

(2009) Dario Cuomo et al.   JOURNAL OF NEUROCHEMISTRY

Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients

(2009) Pershia Samadi et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Metabotropic Glutamate 7 Receptor Subtype Modulates Motor Symptoms in Rodent Models of Parkinson's Disease

(2009) B. Greco et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

(2009) D. Rylander et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

(2009) K Ray Chaudhuri et al.   LANCET NEUROLOGY

NMDA antagonist memantine improves levodopa-induced dyskinesias and “On-off” phenomena in Parkinson's disease

(2009) Sara Varanese et al.   MOVEMENT DISORDERS

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

(2009) Bazoumana Ouattara et al.   NEUROBIOLOGY OF AGING

Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides

(2009) Mohamed Khalil Tamim et al.   NEUROPHARMACOLOGY

Novel Neuroprotective Mechanisms of Memantine: Increase in Neurotrophic Factor Release from Astroglia and Anti-Inflammation by Preventing Microglial Activation

(2009) Hung-Ming Wu et al.   NEUROPSYCHOPHARMACOLOGY

Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

(2009) N. Yamamoto et al.   NEUROSCIENCE

Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain

(2009) V. Di Liberto et al.   NEUROSCIENCE

Rotenone reduces Mg2+-dependent block of NMDA currents in substantia nigra dopamine neurons

(2009) Yan-Na Wu et al.   NEUROTOXICOLOGY

Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons

(2009) Giuseppe Battaglia et al.   PLoS One

Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate

(2009) Monty A. Silverdale et al.   SYNAPSE

Effects of glutamate and α2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats

(2009) Mesbah Alam et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Review: Improving symptom control in early Parkinson’s disease

(2009) Stuart H. Isaacson et al.   Therapeutic Advances in Neurological Disorders

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

(2008) A. Munoz et al.   BRAIN

Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model

(2008) S.T. Warraich et al.   BRAIN RESEARCH BULLETIN

Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions

(2008) L. Truong et al.   BRAIN RESEARCH BULLETIN

NEUROPROTECTIVE EFFECTS OF A SELECTIVEN-METHYL-d-ASPARTATE NR2B RECEPTOR ANTAGONIST IN THE 6-HYDROXYDOPAMINE RAT MODEL OF PARKINSON'S DISEASE

(2008) KR Leaver et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats

(2008) Andreas Gravius et al.   JOURNAL OF NEURAL TRANSMISSION

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism

(2008) John G. Nutt et al.   MOVEMENT DISORDERS

Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

(2008) Jose A. Obeso et al.   MOVEMENT DISORDERS

Molecular mechanisms of L-DOPA-induced dyskinesia

(2008) Peter Jenner   NATURE REVIEWS NEUROSCIENCE

Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats

(2008) Sebastien Lopez et al.   NEUROPHARMACOLOGY

Metabotropic Glutamate Receptors 5 Blockade Reverses Spatial Memory Deficits in a Mouse Model of Parkinson's Disease

(2008) Elvira De Leonibus et al.   NEUROPSYCHOPHARMACOLOGY

Pruning and loss of excitatory synapses by the parkin ubiquitin ligase

(2008) T. D. Helton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat

(2008) Kristin B. Dupre et al.   PSYCHOPHARMACOLOGY

Parkinson's disease and pesticides: a toxicological perspective

(2008) J HATCHER et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

(2007) Pershia Samadi et al.   NEUROBIOLOGY OF AGING

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

(2007) Giovanna Levandis et al.   NEUROBIOLOGY OF DISEASE

Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias

(2007) Pershia Samadi et al.   NEUROPHARMACOLOGY